Qualigen Therapeutics, Inc. QLGN
We take great care to ensure that the data presented and summarized in this overview for Qualigen Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in QLGN
Top Purchases
Top Sells
About QLGN
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Insider Transactions at QLGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2022
|
Michael S. Poirier Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+13.09%
|
$0
$0.57 P/Share
|
|
Jun 14
2022
|
Amy S. Broidrick President/CSO |
BUY
Open market or private purchase
|
Direct |
30,000
+46.51%
|
$0
$0.62 P/Share
|
|
Aug 19
2021
|
Kurt H Kruger Director |
BUY
Open market or private purchase
|
Direct |
8,000
+20.2%
|
$8,000
$1.23 P/Share
|
|
Apr 26
2021
|
Amy S. Broidrick President/CSO |
BUY
Open market or private purchase
|
Direct |
4,500
+50.0%
|
$9,000
$2.03 P/Share
|
|
Apr 20
2021
|
Michael S. Poirier Chairman and CEO |
BUY
Open market or private purchase
|
Indirect |
11,005
+50.0%
|
$11,005
$1.8 P/Share
|
|
Apr 16
2021
|
Christopher L. Lotz Vice President of Finance, CFO |
BUY
Open market or private purchase
|
Direct |
2,700
+17.72%
|
$2,700
$1.86 P/Share
|
|
Dec 29
2020
|
Kurt H Kruger Director |
BUY
Open market or private purchase
|
Direct |
4,000
+28.57%
|
$8,000
$2.94 P/Share
|
|
Nov 23
2020
|
Kurt H Kruger Director |
BUY
Open market or private purchase
|
Direct |
4,600
+43.4%
|
$13,800
$3.46 P/Share
|
|
Nov 20
2020
|
Kurt H Kruger Director |
BUY
Open market or private purchase
|
Direct |
1,400
+50.0%
|
$4,200
$3.55 P/Share
|